Washington University Sleep Study Measures Amyloid-beta and Tau Levels After Suvorexant Administration
A clinical trial conducted at Washington University in St. Louis found that administering the sleep medication suvorexant over two nights in a sleep laboratory led to a measurable reduction of amyloid-beta and tau proteins in the cerebrospinal fluid of healthy adults. The study involved 38 participants aged 45 to 65 who had no sleep disorders or cognitive impairments.
Following a lumbar puncture, participants received either one of two dosages of the orexin receptor antagonist suvorexant or a placebo. Continuous monitoring of cerebrospinal fluid values over a 36-hour period revealed that concentrations of amyloid-beta and tau decreased by approximately 10 to 20 percent.
Higher Doses Decrease Hyperphosphorylated Tau Temporarily Without Altering Sleep Architecture
Higher doses of suvorexant temporarily reduced hyperphosphorylated tau, though this specific decrease did not persist over a full day. In this experimental setup, the medication caused no measurable alteration in the fundamental sleep architecture of the participants.
Brendan Lucey, a neurologist involved in the research, urged caution when interpreting these findings. He emphasized that it is premature to recommend the regular use of sleep medications for Alzheimer’s prevention based on these data, noting that long-term use of such drugs carries a risk of dependency.
Orexin System Activity Correlates With Alzheimer’s Progression
Suvorexant targets the orexin system, a neurotransmitter network that regulates wakefulness. A separate study published in the journal Neurology involving 60 participants demonstrated that higher orexin levels in cerebrospinal fluid correlated with a more unfavorable progression of Alzheimer’s disease over a three-year period.
Participants who exhibited stronger markers of deep sleep—measured by sleep spindle and slow-oscillation activity—showed a weaker correlation between orexin levels and disease severity. Women in that study displayed significantly higher orexin concentrations than men, a notable finding given that women account for nearly two-thirds of all Alzheimer’s cases.
Glymphatic System Clearance Removes Central Nervous System Waste Products
Sleep deprivation is widely recognized in scientific literature as a factor that increases the accumulation of amyloid-beta and tau. Researchers at Duke University have studied the glymphatic system, a network that uses cerebrospinal fluid to clear cellular waste products and damaged proteins from the brain.
Junjie Yao, a biomedical engineer, compared this nocturnal clearance process to a garbage truck driving through a neighborhood to collect waste. Disruptions to this cleaning mechanism are closely linked to neurodegenerative diseases characterized by the buildup of the exact proteins the glymphatic system is designed to remove.
Microglial Inflammation Triggers Sleep Disruptions in Animal Models
Beyond orexin inhibition, researchers are also examining brain inflammation. Investigators at the University of Kentucky found that microglial cells trigger an inflammatory cascade in response to plaques, which subsequently disrupts healthy sleep.
In animal models, temporarily reducing these immune cells using the drug pexidartinib increased sleep duration by more than two hours per night in subjects with Alzheimer’s markers, while the plaque amount remained unchanged. This finding supports the hypothesis that insomnia is not merely a late symptom, but part of a reversible process in the course of the disease.
Keep reading